Cytokinetics (NASDAQ:CYTK) is scheduled to be releasing its earnings data after the market closes on Thursday, November 1st. Analysts expect Cytokinetics to post earnings of ($0.53) per share for the quarter.
Cytokinetics stock opened at $6.60 on Wednesday. The company has a current ratio of 8.95, a quick ratio of 8.95 and a debt-to-equity ratio of 0.41. The company has a market cap of $369.83 million, a price-to-earnings ratio of -2.55 and a beta of 1.42. Cytokinetics has a fifty-two week low of $6.20 and a fifty-two week high of $14.30.
In other news, CEO Robert I. Blum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $7.94, for a total value of $31,760.00. Following the sale, the chief executive officer now directly owns 164,022 shares of the company’s stock, valued at approximately $1,302,334.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 16,500 shares of company stock worth $129,505. Insiders own 5.10% of the company’s stock.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Featured Article: What do investors mean by earnings per share?
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.